Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia

PHASE2CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

June 30, 2013

Study Completion Date

June 25, 2018

Conditions
Carcinoma, Squamous CellAdenocarcinoma of the Esophagus and Gastric Cardia
Interventions
DRUG

Chemotherapy

Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.

RADIATION

Radiochemotherapy

Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.

Trial Locations (1)

14186

Upper Digestive Diseases. Department of surgery, Karolinska University Hospital, Stockholm

All Listed Sponsors
collaborator

University Hospital, Umeå

OTHER

collaborator

Region Örebro County

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Ullevaal University Hospital

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

Oslo University Hospital

OTHER

collaborator

St. Olavs Hospital

OTHER

collaborator

Malarhospital Eskilstuna

UNKNOWN

lead

Karolinska University Hospital

OTHER

NCT01362127 - Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia | Biotech Hunter | Biotech Hunter